Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Moderna

No norovirus vaccine exists—yet. Moderna says it’s ‘one step closer,’ and you may be eligible to participate in its ongoing clinical trial

Up to 21 million people contract norovirus each year in the U.S. alone, the CDC says.

Fortune

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.

Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second presidency.

Investors Business Daily

Stock Market Today: Stocks End Mixed After FOMC Minutes

The minutes from the December Fed meeting signaled central bankers' uncertainty over potential Trump administration policies.

Kiplinger

From analysis to the latest developments in health,
read the most diverse news in one place.

Moderna Stock Is Volatile Amid Bird Flu Developments

Moderna stock has been volatile this week as the first death in the U.S. connected to bird flu was reported. Here's what you need to know.

Kiplinger

What Were the 4 Worst-Performing Stocks in the S&P 500 in 2024?

As 2025 starts to unfold, let's take a look back at the four worst-performing stocks in the S&P 500 from last year.

Barchart

Moderna Shares Spike on H5N1 News—What’s Next for Investors?

MRNA stock surged over 12% on growing bird flu concerns; that rally may not last, but analysts believe the company's pipeline makes the stock a Buy in 2025

MarketBeat

Moderna, BioNTech, Novavax Surge After CDC Reports Two-Week Covid Spike

Moderna stock surged Tuesday after the Centers for Disease Control and Prevention noted a two-week spike in positive Covid tests.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

These Were Analysts' Favorite Stocks For 2024 — How Did They Do?

Analysts certainly picked their favorite S&P 500 stocks for 2024. Too bad they whiffed on 90% of them.

Investors Business Daily

Pfizer Sets Up For A Wild Ride In 2025 Amid Looming Threats From Starboard, Kennedy

Pfizer stock is setting up for a wild ride in 2025 as it faces off with an activist and Robert F. Kennedy Jr. as the possible HHS lead.

Investors Business Daily

Pediatric RSV vaccine trial paused by Moderna amid safety concerns

Five infants required hospitalization, with one needing mechanical ventilation.

Fortune

Dow Jones Rises As Fed Decision Looms; Super Micro Plunges On Nasdaq 100 Removal

The Dow Jones rose Monday as the Federal Reserve's meeting looms later this week. Super Micro plunged on removal from the Nasdaq 100.

Investors Business Daily

Is Moderna Stock Underperforming the Dow?

Moderna has significantly underperformed the Dow over the past year, and analysts are cautious about the stock’s prospects.

Barchart

Dow Jones Futures Rise, Bitcoin Hits High; Palantir Reverses Lower

The Nasdaq held at highs amid weak market breadth. The Fed meeting looms with Palantir and new AI laggard Nvidia in focus.

Investors Business Daily

Palantir Falls Despite Nasdaq 100 News, MicroStrategy Rises; Super Micro Gets The Axe

Palantir, bitcoin play MicroStrategy and Axon Enterprise will join the Nasdaq 100 index. Moderna, Super Micro and Illumina will exit.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Analysts Predict These Will Be Next Year's Top 10 Stocks

Missed out on this year's top S&P 500 stocks? Analysts are already offering up their ideas on which stocks will rule in 2025.

The Guardian - AU

Moderna’s mRNA vaccines to be exempt from advisory committee scrutiny under $2bn Morrison-era deal

Exclusive: Critics say exemption ‘deeply concerning’ and risks creating separate assessment systems

AAP

New vaccine facility a shot in the arm for Australians

Up to 100 million mRNA jabs will be made at Moderna's new plant, with a promise Australia will always be at the top of the vaccine queue for locally-made jabs.

Barchart

2 Vaccine Stocks to Buy on the Dip

Given the cutting-edge pipeline for these two vaccine companies, double-digit slumps in these stocks present a compelling entry point for investors.

Get all your
news in one place.

100’s of premium titles.
One news app.

MarketBeat

Is Biotech’s Bull Run Over? Examining Election Impacts

The biotech sector's breakout attempt post-election reversed sharply, with ETFs like IBB and XBI falling and invalidating the long-term bullish setup.

MarketBeat

Deciphering Disruption: Inside Cathie Wood's Latest Plays

Cathie Wood's recent stock market activity offers a glimpse into her evolving investment strategy and the potential of disruptive technologies.

Barchart

Stocks Settle Sharply Lower on the Outlook for Slower Fed Rate Cuts

The S&P 500 Index ($SPX ) (SPY ) Friday closed down -1.32%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.70%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -2.40%. Stocks retreated Friday, with the S&P 500 and Nasdaq 100 falling to 1-1/2 week...

Barchart

Stocks Tumble as Hawkish Fed and Strong US Economic News Boosts Bond Yields

The S&P 500 Index ($SPX ) (SPY ) today is down -1.17%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.72%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.03%. Stocks today extended Thursday’s decline, with the S&P 500 and the Dow Jones Industrials...

Investors Business Daily

Pfizer, Moderna, BioNTech Take A Beating After Trump Taps Kennedy To Head Up HHS

Pfizer stock and other vaccine shares tumbled Friday morning after Trump picked Kennedy to lead the Department of Health and Human Services.

The Guardian - UK

Pharma shares hit as Trump picks RFK Jr to lead health department

Choice of vaccine critic knocks some of world’s biggest drugmakers including Moderna, AstraZeneca and GSK

Barchart

Moderna Stock Outlook: Is Wall Street Bullish or Bearish?

Moderna has underperformed the broader market and its peers over the past year, and Wall Street analysts are cautious about the stock’s prospects.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.